Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...
Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
Illustrative photo Boehringer Ingelheim Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback